secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001104659-23-037122
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma increases Eclipse revolving credit facility by $2M to $14.5M
---------------------------------------------------------------------------

- Eclipse Amendment No. 4 increased revolving loan commitment by $2M, total facility now $14.5M.
- Borrowing remains subject to borrowing base and reserve requirements.
- Avenue Amendment permits the Eclipse facility increase; no other terms changed.
- Loan agreements dated back to 2019; amendments align with existing debt structure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000110465923037122/0001104659-23-037122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000110465923037122/tm2310570d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-037122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer